hospital serving a population of 675,000. Clinical data included demographics, laboratory parameters, aetiology and stage of liver disease. The aMAP scores were calculated using blood tests at intervals from 1-5 years prior to diagnosis of HCC to classify patients as low, medium or high risk.

**Results** We identified 226 patients diagnosed with HCC between 2010 and 2020. Of these, 181 (80%) were male, median age at diagnosis was 72 years and 215 (95%) were of white ethnicity. Aetiological factors were alcohol 78 (35%), non-alcoholic fatty liver disease 68 (30%), chronic viral hepatitis 54 (24%) and others 20 (9%). There was no prior history of liver disease in 83 (37%). Only 56 patients (25%) were in a formal surveillance programme and just 47 (21%) were of Barcelona Clinic Liver Cancer (BCLC) stage A or lower at diagnosis. However, a medium or high risk aMAP score was identifiable prior to HCC diagnosis in 99% at 1 year, 97% at 3 years and 96% at 5 years. A high risk aMAP score alone was found in 76% at 1 year, 73% at 3 years and in 67% at 5 years prior to diagnosis with HCC.

**Conclusions** Our study examined a ‘real world’ population with HCC, representative of the broad clinical spectrum of UK liver disease. We confirmed most cases were diagnosed at a non-curative stage and were outside of a formal surveillance programme. Importantly, we have shown the vast majority of patients with HCC had demonstrably higher risk aMAP scores, which were identifiable up to 5 years before diagnosis. Use of aMAP scoring could improve targeting of candidates for HCC screening and our findings would support further, prospective evaluation in people with chronic liver disease in the UK.

### PWE-18 METHYLPREDNISOLONE:DIFFERENT OUTCOME IN PREDNISOLONE NON-RESPONSE SEVERE ALCOHOLIC HEPATITIS PATIENTS

Mohamed Elnagar*, Adam Lawson, Paraskvi Mandalou, Nicholas Taylor, Andrew Austin.
Royal Derby Hospital, Derby, UK

**Introduction** Prednisolone treatment of severe alcoholic hepatitis reduces mortality from 18% to 14% at d28 (STOPAH) but not at d90 (30%). Non-response may be due to steroid-resistance which might be overcome by using intravenous methylprednisolone (MePred).

**Methods** All patient with mDF>32 treated with MePred over a 4 year period were reviewed. Patients were treated with prednisolone 40mg daily for 7 days. Prednisolone non-response was defined as d7 Lille model > 0.45 and severe alcoholic hepatitis confirmed by biopsy. Non-responders were given MePred 500mg daily for 3 days followed by prednisonolone 40mg daily for 25 days and prophylactic antibiotics and fluconazole.

**Results** Seven non-responders were given MePred given after biopsy confirmation of alcoholic hepatitis. At d7 post-MePred, Lille score was <0.45 in 5 patients; one died after intracerebral haemorrhage and 4 survived beyond d90. Lille score remained more than 0.45 in 2 patients; one failed to respond and died at d9, the other died of liver failure at d28 despite a fall in bilirubin d7-431 to d28-297 (Figure1). No infective complications were reported. Mortality d28 29% and d90 42%.

### PWE-19 THE ASSOCIATION OF EXERCISE PARTICIPATION WITH CARDIOMETABOLIC HEALTH AND QUALITY OF LIFE IN HEPATITIS C

Kate Hallsworth*, Shion Gosrani, Sarah Hogg, Preya Patel, Aaron Weten, Rachael Welton, Stuart McPherson, Matthew Campbell.
Liver Unit, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK; Newcastle NHR Biomedical Research Centre, Newcastle Upon Tyne, UK; Institute of Health Sciences and Wellbeing, University of Sunderland, Sunderland, UK; Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK

**Introduction** Hepatitis C virus infection (HCV) is associated with an increased risk of cardiovascular disease (CVD) and reduced health-related quality of life (HRQoL). Although physical activity (PA)exercise has been shown to reduce CVD risk and improve HRQoL in patients with liver disease, there is limited data in HCV. We aimed to explore the association between PA/exercise levels, CVD risk and HRQoL in patients with HCV and assess individuals’ attitudes to PA/exercise.

**Methods** Cross-sectional observational study recruiting consecutive patients with HCV from viral hepatitis clinics. Data was collected on CVD risk factors, anthropometry, HRQoL, and the exercise benefits and barriers scale (EBBS).

**Results** 86 patients were recruited (71% male, 94% white, age 52 ±13 years); 49% of the cohort self-reported to be currently active. Although HRQoL was reduced across the cohort, patients that were regularly ‘active’ reported significantly higher HRQoL scores across SF36v2 domains compared to their inactive counterparts (p<0.05). Metabolic and cardiovascular characteristics were no different between groups stratified by PA/exercise status (p>0.05). EBBS scores were similar in the ‘active’ vs ‘inactive’ groups, however, patients categorised as ‘active’ scored significantly higher on the psychological outlook and social interaction sub-scales (p<0.05) than those that were ‘inactive’. There were significant associations between EBBS scores and HRQoL (p<0.05).

**Conclusions** PA/exercise is associated with increased HRQoL in patients with HCV irrespective of clinical parameters. Addressing specific motivators/barriers to exercise for patients will be key to
designing effective PA/exercise interventions in this patient population to ensure maximum uptake and adherence.

**Abstracts**

**PWE-20**

PERCUTANEOUS CHOLECYSTOSTOMY RATES ARE INCREASED FOLLOWING COVID-19 INDUCED DISRUPTION TO ELECTIVE SURGICAL PATHWAYS


10.1136/gutjnl-2021-BSG.210

**Introduction**

The COVID-19 pandemic has led to major service disruptions, including the cessation of elective laparoscopic cholecystectomies (LC), causing delays in managing symptomatic gallstones. We hypothesised that this would lead to an increased need for percutaneous cholecystostomy (PC) for acute cholecystitis.

**Methods**

We performed a retrospective cohort study in a single NHS trust. We included all patients who underwent either LC or PC during the periods of March 1st – August 31st over the years 2019 and 2020. Patient data was obtained from prospectively maintained patient electronic notes. Data are presented as median and interquartile ranges for continuous data and the percentages for categorical data and compared with Mann-Whitney U-test and Fisher's exact tests respectively.

**Results**

We observed a substantial reduction in the number of LC performed in 2020 (n=99) compared to 2019 (n=198), whilst the number of PC performed in 2020 (n=35) was more than double that in 2019 (n=17) (Figure 1). This increase in numbers persisted even after our LC service was restarted. Comparing the patients who underwent PC in both years, there were no significant differences in age (2019: 68 (45-76) vs 2020: 72 (57-81), p=0.41), comorbidities (Charlson comorbidity index≥4: 10 (59%) vs 16 (46%), p=0.56), or in-hospital mortality (2019: 2 (12%) vs 2020: 3 (9%), p=0.99).

**Conclusions**

These results show how the cessation of LC service was directly related to increased numbers of invasive ‘damage control’ procedures for acute cholecystitis, emphasising the importance of maintaining COVID-secure surgical pathways. The numbers of PC remained high even after the restart of LC service, consistent with a ‘COVID shadow’ resulting from interruptions to elective services that impacts patient care for a prolonged period.